1. Figure 6 Differences in glycaemic control with the study drug
versus placebo in cardiovascular outcome studies assessing the safety of
incretin-based therapies in patients with type 2 diabetes mellitus at high risk of cardiac events
Figure 6 | Differences in glycaemic control with the study drug versus placebo in cardiovascular outcome studies assessing the safety of incretin-based therapies in patients with type 2 diabetes mellitus at high risk of cardiac events. Data obtained from Pfeffer et al. (ELIXA)212, Marso et al. (LEADER)65, Marso et al. (SUSTAIN-6)213, Scirica et al. (SAVOR-TIMI 53)215, White et al. (EXAMINE)216 and Green et al. (TECOS)217. EoT, end of treatment.
Muskiet, M. H. A. et al. (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Nat. Rev. Nephrol. doi: /nrneph